1. Home
  2. NBH vs ALLO Comparison

NBH vs ALLO Comparison

Compare NBH & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neuberger Berman Municipal Fund Inc.

NBH

Neuberger Berman Municipal Fund Inc.

HOLD

Current Price

$10.24

Market Cap

314.2M

Sector

Finance

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$2.16

Market Cap

539.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBH
ALLO
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
314.2M
539.4M
IPO Year
2002
2018

Fundamental Metrics

Financial Performance
Metric
NBH
ALLO
Price
$10.24
$2.16
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$8.36
AVG Volume (30 Days)
81.6K
4.6M
Earning Date
01-01-0001
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
34.09
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$141,204.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.47
$0.86
52 Week High
$10.64
$2.80

Technical Indicators

Market Signals
Indicator
NBH
ALLO
Relative Strength Index (RSI) 39.13 46.47
Support Level $10.23 $1.04
Resistance Level $10.37 $2.80
Average True Range (ATR) 0.08 0.19
MACD -0.03 -0.06
Stochastic Oscillator 23.08 8.57

Price Performance

Historical Comparison
NBH
ALLO

About NBH Neuberger Berman Municipal Fund Inc.

Neuberger Berman Municipal Fund Inc is a closed-end management investment company that invests mainly in municipal securities. The company aims to provide common stockholders a high level of current income exempt from Federal income tax.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: